Plus therapeutics announces fda clearance of its investigational new drug application using reyobiqtm for the treatment of childhood brain cancer

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the u.s. department of defense trial will enroll children with high grade glioma and ependymoma houston, june 25, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announced that the u.s. food and drug administration (fda) has cleared its investigational new drug (ind) application (no. 168178) for reyobiqtm (rhenium re186 obisbemeda) for the treatment of pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (hgg) and ependymoma.
PSTV Ratings Summary
PSTV Quant Ranking